Products
Nebratamig Biosimilar Tetraspecific Antibody (4-1BB × PD-L1 × ROR1 × CD3) for Research
Cat No.: GMP-Bios-INN-1292
Anti-TNFRSF9/CD137/4-1BB therapeutic antibody (Pre-made Nebratamig biosimilar,Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 1)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Nebratamig (development code GNC-035) is a tetraspecific antibody targeting 4-1BB (TNFRSF9), PD-L1 (CD274), ROR1, and CD3. It is developed by Sichuan Baili Pharmaceutical and SystImmune for various cancers. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1292-1mg | 1mg | |
| GMP-Bios-INN-1292-10mg | 10mg | |
| GMP-Bios-INN-1292-100mg | 100mg | |
| GMP-Bios-INN-1292-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Nebratamig biosimilar, Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 1), Anti-TNFRSF9/CD137/4-1BB;PDL1/CD274;ROR1;CD3D and CD3E Antibody: Anti-TNFRSF9/CD137/Tumor necrosis factor receptor superfamily member 9/4-1BB ligand receptor therapeutic antibody |
| INN Name | Nebratamig |
| Target | TNFRSF9/CD137/4-1BB;PDL1/CD274;ROR1;CD3D and CD3E |
| Format | Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 1) |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | na;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Sichuan Baili Pharmaceutical;SystImmune |
| Conditions Approved | na |
| Conditions Active | Chronic lymphocytic leukaemia;Haematological malignancies;Non-Hodgkin's lymphoma;Gastric cancer;Leukaemia;Lung cancer;Lymphoma;Ovarian cancer;Solid tumours;Triple negative breast cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
